COLUMBUS, OH — April 10, 2002 — Patients taking the asthma drug Flovent (fluticasone propionate) had fewer hospitalisations, made fewer trips to the emergency room and had less of a need for additional medications to help control symptoms than did patients taking the other two drugs, said Dev Pathak, a study co-author and a professor of pharmacy at Ohio State University.
After analyzing 18 months' worth of insurance claims data for three asthma medications, researchers found that Flovent was the most effective of the medications, and cost nearly two to three times less than the other drugs
Fluticasone propionate is an inhaled corticosteroid — it reduces inflammation in tissues affected by asthma, namely nasal passages and bronchial tissues. The researchers compared fluticasone propionate to the drugs montelukast (Singulair) and zafirlukast (Accolate). Both belong to a class of drugs called leukotriene receptor blockers — drugs that help decrease the inflammation induced by asthma.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!